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Abstract 
Diabetic kidney disease (DKD) is a chronic complication of diabetes mellitus, which is considered a worldwide epi‑
demic. Several studies have been developed in order to elucidate possible genetic factors involved in this disease. 
The FRMD3 gene, a strong candidate selected from genome wide association studies (GWAS), encodes the structural 
protein 4.1O involved in maintaining cell shape and integrity. Some single nucleotide polymorphisms (SNPs) located 
in FRMD3 have been associated with DKD in different ethnicities. However, despite these findings, the matter is still 
controversial. The aim of this narrative review is to summarize the evidence regarding the role of FRMD3 in DKD.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Diabetes mellitus (DM) is a complex and chronic illness 
involving a state of hyperglycemia [1]. Depending on the 
intensity and duration of exposure to hyperglycemia, 
structural lesions may occur in the vascular endothe-
lium and nervous tissue, causing damage and dysfunction 
in multiple organs and tissues, leading to chronic com-
plications [2]. One such complication is diabetic kidney 
disease (DKD), in which there is increased urine excre-
tion of proteins, predominantly albumin [3]. The precise 
mechanism that determines which patients with DM 
would or would not progress to renal failure and dialysis 
has yet to be elucidated. A great effort has been devoted 
to the study of candidate genes related to DKD develop-
ment and progression.
Diabetic kidney disease
DKD, which was initially described as a glomerular dis-
ease characterized by proteinuria, seems to be much 
more than that. Chronic kidney disease (CKD) is defined 
as renal damage resulting from structural or functional 
abnormalities of the kidneys, or glomerular filtration 
rate (GFR) <60  ml/min/1.73  m2 with or without kidney 
damage over a period of time equal to or greater than 
3 months [4]. DKD affects around 25–30 % of individu-
als with DM and is responsible for over a quarter of new 
cases of end-stage renal disease (ESRD) [5, 6]. In 25  % 
of patients with DM, increased urinary albumin excre-
tion (UAE) is observed [7]. Furthermore, low GFR has 
also been reported in a substantial proportion of nor-
moalbuminuric subjects [7–10]. As a result, since 2006 
the American Diabetes Association (ADA) has recom-
mended DKD assessment based on UAE and estimated 
GFR (eGFR) [11, 12]. More recently, ADA has suggested 
that albuminuria must be classified as normal UAE or 
increased UAE [12], instead using the term microalbumi-
nuria [13, 14].
Despite the high prevalence and severity of DKD, not 
all individuals with DM will develop this disease. The 
cumulative incidence of persistent albuminuria (micro-
albuminuria) in patients with type 1 diabetes mellitus 
(T1DM) has been reported from 12.6  % over 7.3  years 
according to The European Diabetes Prospective Com-
plications Study Group (EURODIAB) [15] to 33 % in an 
18-year study carried out in Denmark [16]. It seems that 
T1DM patients who do not develop DKD 10–15  years 
after diagnosis are protected from this complication 
[17]. Furthermore, some subjects with elevated albumi-
nuria will progress to a more severe albumin profile and 
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to normoalbuminuria [18, 19]. Thus, it is believed that 
the presence of risk factors such as hyperglycemia and 
hypertension will lead to DKD in genetically predisposed 
individuals.
The genetics of diabetic kidney disease
Familial clustering of DKD, a multifactorial disease, has 
been reported in several studies, supporting the hypoth-
esis that genetic factors are involved in its pathogenesis 
[20, 21]. However, all the efforts to identify a gene with 
a major effect have been disappointing, possibly because 
several genes are involved, acting synergistically or addi-
tively [22]. For instance, some genes might be related to 
increased albuminuria, and others to GFR decline [23, 
24].
Pezzolesi et al. [25] conducted a genome wide associa-
tion study (GWAS) in Caucasians with T1DM and found 
13 SNPs (single nucleotide polymorphisms) associated 
with DKD. The most significant associations were iden-
tified in variants located near genes from four chromo-
somal regions: CHN2/CPVL on chromosome 7, FRMD3 
on chromosome 9, CARS on chromosome 11, and a 
locus near the IRS2 on chromosome 13. Among those, 
the strongest association was near the FRMD3 gene (4.1 
protein ezrin, radixin, moesin [FERM] domain containing 
3). Nevertheless, Maeda et al. [26] analyzed polymorphic 
variants of this gene [25] in Japanese with type 2 diabetes 
mellitus (T2DM) and did not find any association with 
DKD.
Regardless of extensive evidence of genetic susceptibil-
ity to DKD, the identification of susceptibility genes and 
their variants has had limited success [27, 28]. Mooyart 
et al. [29] conducted a meta-analysis of genetic associa-
tion studies focusing on DKD and found that 21 genetic 
variants were significantly associated with DKD [29], two 
of them in the FRMD3 gene. Other variants were in or 
near the following genes: ACE, AKR1B1, APOC1, APOE, 
EPO, NOS3, HSPG2, VEGFA, CARS, UNC13B, CPVL, 
CHN2, GREM1, and others. Additional variants were 
detected in subgroup analyses: ELMO1 (Asians), CCR5 
(Asians), and CNDP1 (T2DM). However, these associa-
tions were not confirmed by others [30].
The inconsistencies in the results of genetic association 
studies in complex diseases could be due to small sam-
ple sizes or incorrect associations conducting to false or 
spurious positive results [31–34]. Therefore, independent 
replication of positive associations remains essential to 
avoid associations by chance.
FRMD3 gene
The FRMD3 (ID: 257019) is located on chromosome 9, 
band q21.32. It has 21 exons spanning 2,282 base pairs 
(http://www.ncbi.nlm.nih.gov/gene/257019) (Fig.  1). In 
addition, 7 different mRNA sequence splice variants for 
the FRMD3 gene are also shown in Fig. 1.
FRMD3 encodes protein 4.1O, a structural protein 
that is part of the protein 4.1 family [35]. Members of 
this family act as cytoskeletal proteins, maintaining cell 
shape and integrity in a variety of cell types including rat 
nephron cells [36, 37]. However, the role of protein 4.1O 
has not yet been elucidated [38]. It contains a FERM 
domain, which contributes to cell integrity by interact-
ing with transmembrane proteins and actin filaments 
[38, 39]. FRMD3 is detected in different tissues according 
to the Nephromine database (Fig.  2). Studies also have 
reported FRMD3 expression in adult ovaries, fetal skel-
etal muscle, brain, thymus, and human podocytes [35]. In 
addition, FRMD3 expression seems to be decreased in a 
DKD mouse model as compared to non-diabetic mouse 
kidneys (Fig.  3a). FRMD3 is differentially expressed in 
different regions of murine kidney, showing the highest 
level in glomeruli (Fig. 3b).
The 4.1 protein family comprises a group of proteins 
including 4.1R, 4.1G (general type), 4.1B (brain type), and 
4.1N (neuron type) [40]. Erythrocyte protein 4.1 (4.1R) is 
a multifunctional protein essential for maintaining eryth-
rocyte shape, mechanical properties of the membrane, 
deformability, and stability through interactions with the 
spectrin and actin skeleton network [40]. Figure  4 rep-
resents different domains of the FRMD3 protein. The 
FERM domain [38] is an N-terminal 30-kDa domain 
containing binding sites for cytoplasmatic tails of inte-
gral membrane proteins such as band 3 (integral mem-
brane protein involved in spectrin-actin interaction) [41, 
42], glycophorin C (erythroid membrane proteins) [43], 
CD44 (transmembrane glycoprotein found in erythroid 
as well as non-erythroid cells) [44], p55 (abundantly pal-
mitoylated phosphoprotein of the erythroid membrane) 
[43] and calmodulin (a highly conserved calcium-bind-
ing protein, ubiquitously distributed in eukaryotic cells, 
known to affect a plethora of biological functions) [40]. 
An internal 8-10 kDa domain contains the spectrin-actin 
binding activity that is necessary for membrane stabil-
ity [45], and the 22–24 kDa C-terminal domain has been 
reported to bind immunophilin FKBP13 (membrane-
associated protein thought to function as an endoplasmic 
reticulum chaperone) [46] and nuclear mitotic apparatus 
protein (NuMA) [47].
FERM domain proteins have been implicated in 
nephron function. Some of these proteins were described 
as important in the composition of specialized cell–cell 
adhesion complexes. These complexes called slit-dia-
phragms that form between podocyte foot processes 
surrounding glomerular blood vessels have an important 
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role in the function of podocytes, establishing the blood 
filtration barrier in the kidney glomerulus. A reduced 
expression of some FERM domain proteins in zebrafish, 
such as nephrin, podocin or band 4.1/FERM domain 
mosaic eyes resulted in loss of glomerular filtration 
discrimination and abnormal passage of high molecu-
lar weight substances into the glomerular filtrate [48]. 
Another FERM domain protein that has been recently 
related to nephron function is kindlin, an adaptor protein 
that contributes to renal tubulointerstitial fibrosis. This 
protein regulates renal tubular cell plasticity by activation 
of Ras and its downstream signaling pathway [49]. There-
fore, it is possible that FRMD3 might have related func-
tions in kidney.
In the study of Pezzolesi et al. [25], FRMD3 expression 
was increased in proximal renal tubular human cells. 
Expression data for FRMD3 and its co-expressed tran-
scripts suggest that these genes are linked to early devel-
opment of DKD [50]. Moreover, FRMD3 is predicted to 
interact with other genes, suggesting alternative path-
ways in which this gene might act (Fig. 5).
It has been hypothesized that the 9q21.32 locus con-
tributes to glomerular injury early in the pathogenesis 
of DKD [51]. More recently, the rs1888747 risk allele 
was shown to generate a transcription factor binding 
site (TFBS) in a module that is shared by multiple mem-
bers of the bone morphogenetic protein (BMP) signal-
ing pathway, which has previously been implicated in the 
development of DKD [50, 52]. Regarding these findings, 
new pathways are being proposed to explain the role of 
FRMD3 in DKD physiopathology.
Variants in the FRMD3 gene and diabetic kidney disease
Research has been developed to investigate the asso-
ciation of variants in the FRMD3 gene and risk of DKD. 
The main variants studied so far are briefly described 
in Table  1. The polymorphisms rs942278, rs942280, 
rs942283, rs1535752, rs1535753, rs2378658, rs10867977 
and rs10867977 are in strong linkage disequilibrium (LD) 
with each other. The Hapmap project does not show LD 
information for the rs1888746, rs1888747, rs10868025 
and rs13289150 SNPs (http://hapmap.ncbi.nlm.nih.gov).
Fig. 1 Map of the FRMD3 gene in chromosome 9q21‑32. The 21 exons (boxes) are shown from left to right according to the transcription region. 
Black boxes represent encoding regions, the light grey box represents the promoter—5′ UTR region, and the white box represents the 3′ UTR region. 
Vertical arrows show the polymorphic sites associated with diabetic kidney disease. Seven splice variants for the FRMD3 gene are also shown in this 
figure. Figure adapted from http://www.ncbi.nlm.nih.gov/gene/257019 and http://www.ensembl.org
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The first published study regarding variants in FRMD3 
was a GWAS with T1DM patients from the GoKinD 
(Genetics of Kidneys in Diabetes) collection [25]. The 
SNP rs10868025 had the strongest association with DKD 
(OR =  1.45, P =  5.0 ×  10−7) [25]. This SNP involves a 
G for A nucleotide substitution and is located in the 
long arm of chromosome 9 at position 85.4, near the 5′ 
end of FRMD3 [25]. The frequency of the risk allele was 
0.66/0.56 (cases/controls) in the Joslin Diabetes Center 
study (JDC study) and 0.66/0.59 in the George Wash-
ington University study (GWU study) [25]. Two other 
FRMD3 SNPs associated with DKD in the GoKinD col-
lection (rs1888746 and rs13289150) were also associ-
ated with the development of severe nephropathy in the 
DCCT/EDIC (Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complica-
tions) follow-up study [25].
In a meta-analysis, involving three studies including 
1052 cases and 2057 controls, the rs10868025 SNP was 
associated with a lower risk of DKD in European T1DM 
subjects (OR 0.72 [95 % CI 0.64–0.81]) [29], whereas in 
a study with T2DM subjects [26], no significant asso-
ciations between the rs10868025 SNP and DKD were 
detected in four independent Japanese populations. The 
G allele frequency for cases vs. controls in the four popu-
lations studied was: 0.74 vs. 0.73, 0.72 vs. 0.73, 0.67 vs. 
0.73, and 0.70 vs. 0.73 (P  >  0.25 in all cases). The same 
findings were replicated in the Chinese population [53], 
for which no association between FRMD3 SNPs and 
DKD was observed (P = 0.249).
The rs1888747 (C/G) SNP is intergenic, located on the 
long arm of chromosome 9 at position 85.3, near the pro-
moter region of the gene [54]. In the study developed by 
Pezzolesi et  al. [25], a relevant association of rs1888747 
SNP was found with DKD (P  =  6.3  ×  10−7) in Cauca-
sians with T1DM. The frequency of the risk allele (G) 
was 0.68/0.73 for controls/cases in the GWU GoKinD 
and 0.66/0.74 for controls/cases in the JDC GoKinD [25]. 
These findings were strengthened by a meta-analysis 
including three studies analyzing the rs1888747 SNP in 
a total of 1052 cases and 2057 controls [29], which con-
firmed an association of rs1888747 SNP with DKD (OR 
0.74 [95  % CI 0.65–0.83]; P  =  0.602) [29], primarily 
driven by the GoKinD cohort. However, in Japanese indi-
viduals with T2DM, no associations between rs1888747 
SNP and DKD were demonstrated in four different 
groups [26]. The frequency of the G allele for cases/con-
trols was 0.81/0.80, 0.80/0.80, 0.70/0.82 and 0.77/0.81 
(P > 0.05).
In 2011, Freedman et  al. [55] identified that a poten-
tial interaction between FRMD3 and the APOL1 (apoli-
poprotein L1 gene)—MYH9 (non-muscle myosin heavy 
Fig. 2 FRMD3 expressions in a panel of different normal tissues. The graphic represents FRMD3 expression in 65 normal tissues from 353 different 
samples. Data are expressed as fold change, and the number shown after each tissue represents the sample size analyzed for this respective tissue. 
Data were extracted from the Nephromine database (Life Technologies, Ann Arbor, MI; http://www.nephromine.org)
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Fig. 3 FRMD3 expression in kidney. a FRMD3 expression in Hodgins mice according to the presence of diabetic kidney disease. The graphic repre‑
sents mRNA expression from 39 kidney samples. b FRMD3 expression in a normal kidney from Higgins mice according to different kidney regions. 
The graphic represents mRNA expressions from 34 kidney samples. Data are expressed as fold change, and were extracted from the Nephromine 
database (Life Technologies, Ann Arbor, MI; http://www.nephromine.org)
Fig. 4 Different domains of the FRMD3 protein. The various domains are depicted according to the specific length of each domain. The complete 
protein length is 597 amino acids. Figure adapted from http://www.ebi.ac.uk/interpro/protein/A2A2Y4
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chain 9 gene) region on chromosome 22 contributes to 
DKD susceptibility in African Americans. Nevertheless, 
initially no association was found between FRMD3 SNPs 
(rs942280 and others, Table 1) and DKD before adjusting 
for variants on chromosome 20. The results revealed an 
approximately 25–30 % increase in DKD risk with multi-
ple FRMD3 SNPs in subjects not homozygous for MYH9 
risk haplotypes (or APOL1risk variants).
One year later, Williams et al. [30] formed the GEnet-
ics of Nephropathy, an International Effort (GENIE) con-
sortium, to examine reported genetic associations with 
DKD in T1DM previously observed in the GoKinD col-
lection [25]. The samples were provided by the All Ire-
land-Warren 3-Genetics of Kidneys in Diabetes UK and 
Republic of Ireland (UK–ROI) collection and the Finnish 
DKD Study (FinnDiane). None of the analyzed FRMD3 
polymorphisms were associated with DKD (rs1888747 
[P = 0.77 and 0.25, UK–ROI and FinnDiane respectively]; 
rs1086805 [P  =  0.52 for UK–ROI and 0.25 for FinnDi-
ane]) [30].
Further evidence of the role of FRMD3 in kidney dis-
ease came from the study of Park et al. [56]. In this study, 
the authors aimed to find candidate genetic determinants 
of renal function in 1007 individuals from 73 extended 
families of Mongolian origin [56]. The strongest associa-
tions found were with rs17400257 SNP (P = 7.21 × 10−9) 
and rs6559725 SNP (P =  9.12 ×  10−7). The rs17400257 
SNP is located 45  kb downstream of FRMD3, and 
rs6559725 SNP is located in the intronic region of 
FRMD3 [56].
After the initial findings in T1DM in 2009 [25], Pez-
zolesi et al. [51] proceeded to examine whether the SNPs 
at these susceptibility loci were associated with DKD in a 
T2DM Family Collection. The 9q21.32 locus was signifi-
cantly associated with high microalbuminuria, proteinu-
ria, and ESRD [51]. Among diabetic family members, 
rs1888747 SNP on chromosome 9q21.32 was associated 
with advanced nephropathy (P  =  0.029). Furthermore, 
when the definition of DKD was expanded to include 
individuals with high microalbuminuria, the strength of 
the association improved significantly [51].
Martini et al. [50] proposed a transcriptional link that 
might explain how the rs1888747 SNP in FRMD3 influ-
ences transcriptional regulation within the bone mor-
phogenetic protein (BMP)-signaling pathway. FRMD3 
transcript levels decreased significantly with the pro-
gression of DKD (P  <  0.02). FRMD3 gene expression 
was studied by comparing renal biopsies in a group 
of 22 Pima Indians with T2DM and normal GFR and 
a cohort of seven participants with T2DM and CKD 
stage 3 [50]. Hierarchical clustering using the FRMD3 
coexpressed transcripts detected two distinct clusters. 
In cluster 1, presenting higher ∆ACR/year (∆ albumin-
to-creatinine ratio per year), gene expressions of seven 
out of the eight BMP pathway genes (BMPR2, CREB1, 
KRAS, MAP3K7, PRKAR2B, SMAD5, and XIAP) were 
lower than the expressions of these genes in cluster 2. 
These findings suggest a common molecular mecha-
nism responsible for the coregulation of FRMD3 and 
several BMP pathway members [50]. Additionally, in 
silico comparison of sequence variants of the risk allele 
identified a potential homeodomain factor (HOMF) 
transcription factor binding site (TFBS) covering the 
SNP position [50]. The rs1888747 SNP affects protein 
binding, suggesting the generation of a TFBS by this 
particular SNP [50]. However, the mechanism mediat-
ing the connection between FRMD3 and BMP pathway 
members is still unknown, and no data are available 
at protein, RNA, or microRNA levels to elucidate this 
association [50]. It should be noted that Palmer and 
Freedman [54] suggested that the framework proposed 
by Martini et al. [50] is limited to genes with known or 
predicted functional roles.
Fig. 5 FRMD3 protein interaction view networks in humans. The 
figure represents predicted interactions of FRMD3 with different 
proteins using medium confidence algorithms. Lines of different 
colors indicate that the respective interaction was predicted using 
more than one algorithm/tool. RASEF RAS and EF‑hand domain 
containing, NPAP1 nuclear pore associated protein 1, KIF27 kinesin 
family member 27, PSAT1 phosphoserine aminotransferase 1, CPVL 
carboxypeptidase, vitellogenic‑like, TLE1 transducin‑like enhancer of 
split 1 (E(sp1) homolog, Drosophila), SLC28A3 solute carrier family 28 
(sodium‑coupled nucleoside transporter), member 3, GNAQ guanine 
nucleotide binding protein (G protein), q polypeptide, GNA11 
guanine nucleotide binding protein (G protein), alpha 11 (Gq class), 
C9orf85 chromosome 9 open reading frame 85. Figure extracted from 
database Search Tool for the Retrieval of Interacting Genes/Proteins 
STRING.db (http://string‑db.org/)
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Table 1 FRMD3 variants studied in the context of diabetic kidney disease
Variant Reference Ethnicity Sample description Chromossome 9a 
position
Risk allele P value Odds ratio (95 % CI)
rs942278 Freedman et al. [55] African–American 966 cases (T2DM‑DKD)
1032 controls (Non‑DM, 
non DKD)
85906066 T 0.0023 1.30 (1.11–1.53)
rs942280 85905861 G 0.00070 1.28 (1.09–1.51)
rs942283 85905666 C 0.0014 1.25 (1.07–1.47)
rs1535752 85905253 T 0.013 1.27 (1.03–1.57)
rs1535753 85905060 T 0.0024 1.24 (1.06–1.46)
rs2378658 85904778 C 0.0040 1.25 (1.06–1.46)
rs10867977 85907516 G 0.022 1.31 (1.06–1.62)
rs1888746 Hu et al. [53] Chinese 622 cases (378 T2DM‑
DKD and 244 DKD 
and retinopathy)
280 controls (>10 years 
T2DM)
86155392 C 0.66 0.93 (0.60–1.38)




86155392 C 0.02 NAb
rs1888747 Maeda et al. [26] Japanese 754 cases (T2DM‑ DKD 
and retinopathy) 
and 558 controls 
(T2DM—only retin‑
opathy)
86155551 G 0.10 1.24 (0.96–1.61)
449 cases (T2DM—DKD 
and retinopathy) and 





progressed to overt 




300 cases (T2DM‑DKD) 
and 224 controls 
(normoalbuminuria 
and >10 years T2DM)
0.43 0.87 (0.61–1.23)
Pezzolesi et al. [25] Caucasian 0.00000067 1.45 (1.25–1.67)
Williams et al. [30] Caucasian UK—ROI: 903 cases 
(DKD, retinopathy 
and ESRD) and 1001 
controls (T1DM)
FinnDiane: 1289 cases 
(ESRD and macroal‑
buminuria) and 1577 
controls (normoalbu‑
minuria)
Reanalysis of US GoKind 
data: 905 cases (DKD) 
and 898 controls 
(T1DM)
0.24 1.06 (0.96–1.17)
Pezzolesi et al. [58] Caucasian 743 cases (T2DM‑ 427 
microalbuminuria 
and 316 proteinuria/




Pezzolesi et al. [51] Caucasian 382 controls (non 
T2DM) and 416 cases 
(T2DM‑ DKD)
0.0014 NAd
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Recently, a GWAS was performed by Palmer et al. [57] 
with the objective of evaluating candidate DKD suscep-
tibility genes in African Americans. The SNPs selected 
were the same previously studied in European ancestries 
by Pezzolesi et al. [25]. The results showed that SNPs in 
FRMD3 tended toward association with T2DM-ESRD 
(P < 0.05).
Conclusions
Even though not much is known about the FRMD3 
gene, some studies provide insights into the relationship 
between FRMD3 variants and DKD. Major findings in 
the African American population show an association 
between DKD and many SNPs, especially rs10867977 
(OR 1.31, 95 % CI 1.06–1.62). In the Japanese population, 
a significant association was found only at rs1888747, 
whereas in Caucasians three SNPs have been found 
to be associated with DKD (rs1888746, rs1888747, 
rs10868025). Nevertheless, considering all SNPs and 
ethnic groups analyzed, the strongest association was 
found in Caucasians with polymorphisms rs1888747 and 
rs10868025. However, the data produced so far is not suf-
ficient to ascertain a role of FRMD3 in DKD pathogen-
esis. Also, because the relationship between the FRMD3 
gene and DKD was recently detected, very few studies 
focusing on its mRNA and protein expression are avail-
able. Some limitations regarding the development of 
genetic association studies for diabetic complications 
could explain differences among studies which evalu-
ated the FRMD3 gene. The first limitation involves dif-
ferences in the definition of DKD among the studies. The 
recommended prognosis of DKD is determined by two 
parameters, GFR and albuminuria levels. Nevertheless, 
the majority of studies frequently use only one of these 
Table 1 continued
Variant Reference Ethnicity Sample description Chromossome 9a 
position
Risk allele P value Odds ratio (95 % CI)




rs10868025 Pezzolesi et al. [25] Caucasian 86164176 A 0.00005 1.45 (1.25–1.67)
Williams et al. [30] Caucasian 0.19 1.06 (0.97–1.17)
Pezzolesi et al. [51] Caucasian 0.0039 NAe
Pezzolesi et al. [58] Caucasian 0.90 0.99 (0.84–1.16)
Maeda et al. [26] Japanese 754 cases (T2DM‑DKD 
and retinopathy) and 
558 controls (T2DM‑ 
only retinopathy)
0.31 1.12 (0.89–1.42)
449 cases (T2DM‑DKD 
and retinopathy) and 





progressed to overt 




300 cases (T2DM‑DKD) 
and 224 controls 
(normoalbuminuria 
and >10 years T2DM)
0.33 0.85 (0.62–1.18)
Hu et al. [53] Chinese 0.25 0.91 (0.76–1.07)
Moyaart et al. [29] Caucasian 0.12 0.72 (0.64–0.81)
rs13289150 Pezzolesi et al. [25] Caucasian 83549513 A 0.05 NAc
NA not applicable, T2DM type 2 diabetes mellitus, T1DM type 1 diabetes mellitus, DKD diabetes kidney disease, ESRD end-stage renal disease
a Adapted from on the hg19 genome assembly
b Hazard ratio 1.33
c Hazard ratio 1.23
d Z score 3.19
e Z score 2.88
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parameters to classify the disease. Moreover, differences 
in confounding factors such as DM duration and glyce-
mic control could also influence the results.
The functional context of FRMD3 could be experi-
mentally elucidated by several approaches. One possi-
bility is to perform functional studies in kidney cells to 
evaluate the consequences of FRMD3 gene silencing/
overexpression. Knockout/transgenic mouse models may 
also contribute to clarify FRMD3 function in the kidney. 
Fine mapping studies of GWAS data could identify new 
functional FRMD3 polymorphisms associated with DKD. 
Moreover, designing studies would be helpful to deter-
mine what molecules could be interacting with FRMD3 
aiming to further increase knowledge of the mechanisms 
and pathways in which the gene is involved and its rela-
tion to diseases, as suggested by Martini et al. [50].
In summary, FRMD3 is a strong candidate gene for 
DKD. However, further studies are needed to explain the 
pathways through which FRMD3 influences the onset of 
this diabetic complication.
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